Security key
03969F109
Arcus Biosciences, Inc. - Common Stock (RCUS)
CUSIP: 03969F109
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 119,078,221
- Total 13F value
- $2,572,356,108
- Share change
- -3,140,595
- Put/Call ratio
- 46%
- SEC-reported price per share
- $21.60
- Number of holders
- 208
- Value change
- -$79,675,032
- Number of buys
- 113
- Number of sells
- 88
- Shares outstanding
- 122,470,452
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
208
Top holders
10
RCUS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Arcus Biosciences, Inc. SEC filings
Arcus Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03969F109
Recent filing periods:
Ownership snapshot
Top reported holders of RCUS - Arcus Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GILEAD SCIENCES, INC.
Disclosed value leader
GILEAD SCIENCES, INC.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
3/4/5
Lead comparable stake: 26%
13D/G row: GILEAD SCIENCES, INC.
Showing 1-6 of 15 holder rows.
Quick read
GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 26%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GILEAD SCIENCES, INC.'s linked filing trail.
Comparable ownership
Top 5
GILEAD SCIENCES, INC.
26%
BlackRock, Inc.
10%
Point72 Asset Management, L.P.
4.1%
VANGUARD GROUP INC
6.5%
SUVRETTA CAPITAL MANAGEMENT, LLC
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
26%
from 13D/G
|
$748,852,031
31,424,760 shares
|
— | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
10%
from 13D/G
|
$357,399,743
14,997,891 shares
|
— | 31 Dec 2025 |
| Point72 Asset Management, L.P. |
13F
13D/G
Company
|
4.1%
from 13D/G
|
$78,162,400
3,280,000 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
6.5%
|
$189,755,288
7,962,874 shares
|
— | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
Company
|
4.2%
|
$123,650,486
5,188,858 shares
|
— | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
4.2%
|
$123,546,849
5,184,509 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
208
Shares
119,078,221
Rows available
208
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
208
Q1 2026 holders
208
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend